Christophe Quéva

Christophe Quéva has a diverse and extensive work experience in the biopharmaceutical industry. Christophe is currently the Chief Scientific Officer at DEM Biopharma, Inc. since September 2022. Prior to that, they served as a Venture Partner at Bpifrance starting from May 2021.

Christophe Quéva had previously held the position of Chief Scientific Officer at Oncorus from October 2017 to September 2022, where they made significant contributions in scientific leadership. Before that, they were the Chief Scientific Officer at iTeos Therapeutics SA from August 2015 to September 2017, where they played a vital role in driving the company's scientific strategies.

Christophe also has experience at Gilead Sciences, where they held various roles including Director Biology, Translational Medicine from May 2015 to July 2015, and Director of Biology, Oncology and Inflammation from June 2012 to April 2015.

Earlier in their career, Christophe Quéva worked as a Consultant in scientific and strategic consulting from January 2012 to June 2012, and as a Director Research, Hematology Oncology Therapeutic Area at Amgen from September 2006 to December 2011. Christophe also served as an Associate Director at AstraZeneca R&D Boston, where they held the positions of Associate Director from May 1998 to September 2001, and Associate Director from September 2001 to September 2006.

Christophe Quéva began their career as a Post-doctoral fellow at the Fred Hutchinson Cancer Research Center, where they worked from February 1993 to May 1998, gaining valuable research experience.

Christophe Quéva obtained a PhD in Health sciences from the University of Lille 1 Sciences and Technology between 1989 and 1993.